Eurofins Scientific Acquires Transplant Genomics Inc. to Expand Molecular Diagnostics Portfolio

On June 25, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that Eurofins Scientific, a global leader in bioanalytical testing sciences, announced the successful acquisition of Transplant Genomics Inc. (TGI). TGI is a molecular diagnostics company dedicated to improving organ transplant outcomes through genomics-guided, non-invasive continuous monitoring.

TGI offers innovative non-invasive testing services for asymptomatic inflammation and rejection following kidney transplantation. This testing service will complement the global portfolio of transplant diagnostic products. The vast market provides an ideal platform for Eurofins to launch TGI’s TruGraf blood test, which can reliably rule out subclinical kidney rejection in kidney transplant recipients with stable renal function. Reportedly, the Centers for Medicare & Medicaid Services (CMS) has expressed support for the upcoming launch of TruGraf.

TruGraf is a blood-based diagnostic test developed by TGI in collaboration with the Comprehensive Transplant Center at Northwestern University and the Scripps Research Institute. For patients with stable kidney function, physicians can confidently use TruGraf after kidney transplantation, thereby avoiding invasive biopsies for the assessment of graft rejection. This technology also holds promise for application in other types of organ transplants to detect both subclinical and clinical rejection.

Dr. Gilles Martin, CEO of Eurofins, stated: “We are delighted to welcome Transplant Genomics and its distinguished team of scientists to the Eurofins Group. This acquisition significantly strengthens our laboratory network’s capabilities, reinforces Eurofins’ leadership position in the transplant testing market, and enhances our ability to deploy the latest scientific advancements for the benefit of patients.”

Dr. Stan Rose, CEO of TGI, stated, “TGI is delighted to join Eurofins, the global leader in bioanalytical testing science. Becoming part of the Eurofins Group will enable us to launch the TruGraf subclinical kidney rejection test under optimal conditions, allowing us to improve organ transplant outcomes for as many patients as possible.”

Dr. Michael Abecassis, founder of TGI, stated, “When we co-founded TGI, our primary and sole objective was to ensure that our patients would one day benefit from our research. Through this transaction, Eurofins will help TGI fully realize its initial goal.”

Transplant Genomics Inc. is a molecular diagnostics company dedicated to improving organ transplant outcomes, with an initial focus on kidney transplant recipients. In collaboration with the organ transplantation community, TGI is commercializing a suite of tests designed to diagnose and predict the immune status of transplant recipients. The test results will provide clinicians with actionable insights to optimize immunosuppressive therapy, enhance patient care, and improve graft survival rates.

Eurofins Scientific is a leader in CRO services for food, environmental, pharmaceutical, and cosmetic product testing, as well as agricultural sciences. Eurofins is also one of the world’s leading emerging enterprises specializing in clinical diagnostic testing. With approximately 45,000 employees across more than 800 laboratories in 47 countries, Eurofins offers over 200,000 analytical methods. Through R&D and acquisitions, the Eurofins Group leverages cutting-edge technologies in biotechnology and analytical chemistry to provide customers with unique analytical solutions and the most comprehensive testing methodologies.

(Compiled by Zhang Jing)